Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Six more countries add Prevenar to their immunisation programmes

This article was originally published in Scrip

Executive Summary

Wyethhas praised six countries for including its seven-valent pneumococcal conjugate vaccine, Prevenar, in their immunisation programmes. Cyprus, Bahrain, Hungary, Ireland, Slovakia and Sweden have become the latest countries to announce that they will routinely immunise infants against pneumococcal disease using Prevenar. This brings the total number of countries to include the vaccine in their programmes to 24, according to Wyeth. The company also points to Germany for proof of the vaccine's worth. "Since the introduction of PCV7 into Germany's paediatric immunisation schedule in 2006, there has been a 50% reduction in vaccine-type invasive pneumococcal disease in children younger than two years old compared with a pre-vaccine base-line", the company says. Pneumococcal disease leads to 1.6 million deaths a year across the world.

You may also be interested in...



Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines

Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.

German HTA Queries Polivy Benefits Amid Lack Of Evidence

Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.

Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy

In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC003397

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel